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Background/Aims: The diagnostic proton pump inhibitor 
test (PPI test) is a method used in diagnosing gastroesopha-
geal reflux disease (GERD). This study aimed to determine 
the appropriate dose of lansoprazole for use in the diagnos-
tic test for GERD. Methods: This study was a randomized, 
controlled, multicenter trial in the Daegu-Gyeongbuk area. 
Patients with typical reﬂ  ux symptoms such as regurgitation 
and heartburn for at least three months were enrolled in this 
study. Patients were divided into two groups, the erosive re-
ﬂ  ux disease (ERD) group and the non-erosive reﬂ  ux disease 
(NERD) group, and randomized to 14 days of treatment with 
lansoprazole at a dose of 15 mg, 30 mg or 60 mg once daily. 
The PPI test was considered positive if the patient’s symp-
toms improved by more than 50%. Results: A total of 218 pa-
tients were enrolled, and analysis was performed on the 188 
patients who completed the study. The PPI test was positive 
in 93.2% of the ERD group and 87.2% of the NERD group. A 
positive PPI test was observed in 91.7%, 89.4%, and 87.2% 
of the 15 mg, 30 mg, and 60 mg groups, respectively. Signiﬁ  -
cant symptom score changes were observed starting on day 
8 for the 15 mg, 30 mg, and 60 mg groups. Conclusions: In 
this multicenter, randomized study of Korean patients, the 
standard dose of lansoprazole was as effective as a high 
dose of lansoprazole in relieving the symptoms of GERD, re-
gardless of the presence of ERD, by day 14 of treatment. (Gut 
Liver 2011;5:302-307)
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INTRODUCTION
Gastroesophageal reflux disease (GERD) is a condition that 
develops when reflux of the stomach contents causes symptoms 
and/or complications based on the Montreal definition and clas-
sification.
1 The most common symptoms associated with GERD 
are heartburn and regurgitation. 
The prevalence of GERD in Western countries is higher than 
in Eastern countries at about 10-20%.
2 However, the prevalence 
of GERD depends on the diagnostic tools for establishing the 
diagnosis of GERD. 
The available diagnostic tests for GERD include upper endos-
copy, ambulatory 24-hour esophageal pH monitoring, barium 
esophagogram, and multichannel intraluminal impedance with 
a pH sensor. Endoscopy allows assessment esophageal mucosal 
injury. However, endoscopy is invasive, expensive (in some 
Western countries) and technically demanding, and the sensitiv-
ity for diagnosing GERD is low, about 50%. Also, ambulatory 
24-hour pH monitoring also is time-consuming and an invasive 
method and has a low sensitivity in cases with mild or non-ero-
sive reflux disease. In addition, pH monitoring has inter-observ-
er and intra-procedure variation. The proton pump inhibitor (PPI) 
test is a simple and noninvasive method for diagnosing GERD 
and sensitivity of the PPI test ranges from 27% to 89% and the 
specificity from 35% to 73%.
3-8 But, proper dose and duration of 
PPI for PPI test has not been fully evaluated.
This study was performed to evaluate the proper dose and 
duration of PPI test according to erosive esophagitis in Korean 
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MATERIALS AND METHODS
This study was a randomized, controlled, multicenter trial 
from January 2007 to December 2007. The study was carried 
out at five tertiary referral centers in the Daegu and Gyeongbuk 
areas of Korea after Institutional Review Board (IRB) approval 
of the study. We enrolled 218 patients with typical reflux 
symptoms such as regurgitation and heartburn for at least three 
months and that had the symptoms for two or more days dur-
ing a seven-day interval preceding commencement of the study 
(Fig. 1). Patients were eligible for the study if they were between 
19 and 75 years of age. All patients provided written consent 
to participate in the study. The exclusion criteria were: patients 
that declined study enrollment; a pregnancy or breast-feeding; 
patients that could not undergo esophagogastroduodenoscopy; 
active gastric ulcer or duodenal ulcer; complications of GERD 
such as an esophageal stricture or Barrett’s esophagus; LA clas-
sification D GERD; warning signs such as anemia, weight loss, 
or severe dysphagia; severe allergy history for a drug; history of 
gastric or esophageal surgery; impaired hepatic or renal func-
tion; uncontrolled diabetes mellitus or hypertension; severe con-
comitant cardiovascular, hepatic, renal, pulmonary, malignant 
or hematological disease; recent (within 1 week) treatment with 
a proton pump inhibitor, H2 blockers, prokinetics, sulcrafate, 
steroid, antibiotics, non-steroid anti-inflammstory drugs, anti-
histamine, angiotensin-converting enzyme inhibitor or warfa-
rin; alcohol or drug abuse. 
We divided the patients into two groups, erosive reflux dis-
ease and non-erosive reflux disease group after esophagogastro-
duodenoscopy (EGD). Patients took lasoprazole 15 mg or one 30 
mg or 60 mg once daily before breakfast for 14 days, according 
to the randomization schedule based on sequential patient num-
bers. 
The severity of symptom was evaluated before the study, 
based on the information in a symptom diary, by the patient. 
The patients were asked to keep a diary in which they recorded 
the severity of symptoms associated GERD throughout the 
study. The symptoms scale in the diary included 2 variables, re-
gurgitation and heartburn. The symptom severity was graded by 
the patient as none=0, mild=1 (symptom did not last long and 
was easily tolerated), moderate=2 (symptom caused discomfort 
but not interrupted usual activities), severe=3 (symptoms caused 
interference of usual activities) and disabling symptom=4 (dis-
abling symptom caused significant interference of usual activi-
ties). The maximum score was 8 (regurgitation 4+heartburn 4). 
Patients that did not take their medication of keep their diary at 
a frequency of at least 75% (protocol violations) were excluded 
from the study. The PPI test was considered positive if the pa-
tient’s symptoms improved by more than 50%.
All adverse symptoms were evaluated and classified as mild 
(transient and easily tolerated), moderate (caused considerable 
interference with usual activity) or severe (caused considerable 
interference with usual activity and may have been incapacitat-
ing or life-threatening). All efficacy variables were analyzed ac-
cording to the per-protocol approach. 
RESULTS
A total of 218 patients entered this study, and 188 patients 
were eligible for analysis. A total of 30 patients were excluded 
Fig. 1. A schematic diagram of study 
design.
Table 1. Clinical Characteristics by Daily Dosage of Lansoprazole
Characteristic 15 mg 30 mg 60 mg p-value
Female, n (%) 34 (58.6) 40 (58.8) 36 (58.1) 0.996
Age, mean±SD, yr   50.7±10.7   49.1±12.5   50.0±11.9 0.742
BMI, mean±SD, kg/m
2 23.2±2.9 23.7±2.9 22.9±2.6 0.197
Alcohol: yes, n (%) 16 (27.6) 21 (30.9) 20 (32.3) 0.850
Current smoker, n (%) 12 (20.7) 10 (14.7) 11 (17.7) 0.678
Total symptom score, mean±SD   7.5±5.7   7.5±5.3   7.6±5.6 0.987
Compliance, mean±SD, % 97.4±9.2 98.1±5.5 97.0±7.3 0.695
SD, standard deviation; BMI, body mass index.304  Gut and Liver, Vol. 5, No. 3, September 2011
from the analysis because of protocol violations. There were no 
patients who stopped taking the medication because of adverse 
events. 
The mean age of the 188 patients was 49.9±11.8 years. Male 
to female ratio was 78:110. Heartburn and regurgitation was 
observed in 171 (91%) and 151 (80.3%) of patients, respectively.
The number of patients in ERD and NERD group was 70 
(37.2%) and 118 (62.8%) patients. The erosive esophagitis by LA 
classification in ERD group consisted of LA-A in 51 patients, 
LA-B in 16 patients, and LA-C in 3 patients. 
Clinical characteristics between ERD and NERD group were 
well matched at baseline for age, body mass index, and total 
symptom score. However, female was predominant in NERD 
group and alcohol consumption and current smoking status was 
more frequently observed in ERD group. The three groups based 
on the dose of PPI were well matched at baseline (Table 1).
A positive PPI test was observed 93.2% of the ERD group and 
87.2% of the NERD group during 2 weeks treatment (Table 2). 
There was no difference between two groups (p>0.05).
The baseline mean symptom score by heartburn and regurgi-
tation in ERD group and NERD group was 8.0±6.3 and 7.3±5.0, 
respectively (Table 3). The day to significant symptom score 
change from baseline was 6th day in ERD group and 11th day 
in NERD group (Table 3, Fig. 2). 
A positive PPI test by dosage of lansoprazole was noted 
Table 2. Cumulative Improvement over 50% of the Initial Symptom 
Score by Erosion during a 2 Week Treatment
Day
ERD (n=70) NERD (n=118)
No. Cumulative % No. Cumulative %
2 35 50.0 55 46.6
3 42 60.0 60 51.3
4 50 71.4 69 58.5
5 48 68.6 75 63.6
6 55 78.6 79 66.9
7 51 73.9 78 66.1
8 53 76.8 86 73.5
9 62 88.6 86 73.5
10 60 85.7 91 77.8
11 63 90.0 91 79.8
12 62 88.6 92 81.4
13 61 89.7 91 82.0
14 55 93.2 82 87.2
ERD, erosive reflux disease; NERD, non-erosive reflux disease. 
Table 3. Daily Change in the Mean Symptom Score by Erosion
Day
ERD (n=70) NERD (n=118)
Mean±SD p-value Mean±SD p-value
Baseline 8.0±6.3 - 7.3±5.0 -
2 4.6±4.5 - 4.8±4.8 -
3 3.9±3.9 0.395 4.6±5.1 -
4 3.1±3.7 0.054 4.2±4.6 -
5 3.1±4.1 0.056 4.0±4.8 -
6 2.6±3.6 0.005 3.7±4.6 -
7 2.5±3.6 0.000 3.6±4.5 0.490
8 2.4±3.1 0.000 2.9±3.6 0.010
9 2.0±2.8 0.000 3.1±4.2 0.058
10 1.8±2.6 0.000 2.9±4.4 0.036
11 1.6±2.5 0.000 2.6±4.1 0.002
12 1.5±2.6 0.000 2.7±4.0 0.003
13 1.5±2.2 0.000 2.3±3.6 0.000
14 1.3±2.0 0.000 2.0±3.3 0.000
ERD, erosive reflux disease; NERD, non-erosive reflux disease; SD, 
standard deviation.
Fig. 2. Daily change in the mean symptom score for all subjects: ero-
sive reflux disease (ERD) vs. non-erosive reflux disease (NERD). The 
X axis shows medication day from baseline (visit 2), and the Y axis 
shows the mean symptom score for each day. 
Fig. 3. Daily change in the mean symptom score for all subjects on 
each proton pump inhibitor (PPI) dose. The X axis shows medication 
day from baseline (visit 2), and the Y axis shows the mean symptom 
score for each day.Lee SH, et al: Appropriate Dose of Diagnostic Proton Pump Inhibitor Test  305
DISCUSSION
GERD is a condition characterized by heartburn or regurgita-
tion caused by esophageal exposure to the acidic gastric con-
tents.
9 The most common symptoms associated with GERD are 
heartburn and regurgitation. However, the symptoms in Asian 
countries are different from western countries; atypical symp-
toms including hoarseness, atypical chest pain, dysphagia, and 
globus sensation are more common. 
The prevalence of GERD in the West is higher than in Asian 
91.7% in 15 mg group, 89.7% in 30 mg group, and 87.2% in 60 
mg of lansoprazole group (p>0.05, Table 4, Fig. 3). 
The number of days to significant symptom score change 
was 8th day for the 15 mg, 30 mg, and 60 mg group (Table 5). 
Adverse symptoms observed in 6, 4, and 6 patients in the 15 
mg, 30 mg, and 60 mg group, respectively. Common adverse 
symptoms were diarrhea and headache. However, most of ad-
verse symptoms were mild. One moderate adverse symptom was 
observed in 30 mg and 60 mg group, respectively. 
Table 4. Improvement over 50% of the Initial Symptom Score by Daily Dosage of Lansoprazole
Day
15 mg (n=58) 30 mg (n=68) 60 mg (n=62)
No. Cumulative % No. Cumulative % No. Cumulative %
2 30 51.7 27 39.7 33 53.2
3 32 56.1 34 50.0 36 58.1
4 34 58.6 45 66.2 40 64.5
5 38 65.5 47 69.1 38 61.3
6 38 65.5 49 72.1 47 75.8
7 38 66.7 47 69.1 44 71.0
8 40 71.4 53 77.9 46 74.2
9 40 70.2 58 85.3 50 80.6
10 44 77.2 58 85.3 49 79.0
11 45 80.4 58 85.3 51 85.0
12 46 82.1 58 87.9 50 82.0
13 47 85.5 54 84.4 51 85.0
14 44 91.7 52 89.7 41 87.2
Table 5. Daily Change in the Mean Symptom Score by Dosage of Lansoprazole
Day
15 mg (n=58) 30 mg (n=68) 60 mg (n=62)
Mean±SD p-value Mean±SD p-value Mean±SD p-value
Baseline 7.5±5.7 - 7.5±5.3 - 7.6±5.6 -
2 4.7±5.3 - 4.8±4.4 - 4.6±4.4 -
3 4.0±4.5 - 4.4±5.3 - 4.6±4.2 -
4 3.8±4.7 - 3.6±4.1 0.592 4.0±4.3 -
5 3.5±4.7 0.333 3.5±4.5 0.327 3.9±4.4 -
6 3.4±4.3 0.218 3.2±4.6 0.168 3.4±3.9 0.183
7 3.3±4.1 0.218 3.3±4.6 0.188 3.2±3.8 0.088
8 2.9±3.8 0.044 2.5±3.2 0.002 2.9±3.5 0.022
9 2.9±4.0 0.041 2.4±3.6 0.004 2.8±3.8 0.018
10 2.3±3.5 0.000 2.1±3.4 0.001 3.1±4.5 0.118
11 2.4±3.7 0.001 1.9±3.1 0.000 2.4±4.2 0.004
12 2.3±3.5 0.000 2.0±3.4 0.000 2.5±3.9 0.006
13 2.0±3.3 0.000 1.6±2.0 0.000 2.5±4.0 0.007
14 1.6±2.5 0.000 1.3±1.7 0.000 2.2±4.1 0.005
SD, standard deviation.306  Gut and Liver, Vol. 5, No. 3, September 2011
this study. 
Various types of PPIs such as omeprazole, lansoprazole,
8 
rabeprazole,
16 and esomeprzole
7 are used for the PPI test. The 
data on the PPI test using second generation medications was 
spare and conflicting because the majority of the PPI tests were 
performed using omeprazole.
3-8,14 However, the PPI test using 
second generation medication was as sensitive as the PPI test 
using omeprazole.
7,8,16
The limitation of this study is lack of gold standard for the 
diagnosis of GERD and the definition of positive PPI test is de-
termined arbitrarily. 
This randomized study was performed to evaluate the proper 
dose and duration of PPI test according to erosive esophagitis. 
The results showed that standard dose PPI test using lansopra-
zole regardless of the presence of erosive esophagitis was as ef-
fective as high-dose PPI testing in Korean patients.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
ACKNOWLEDGEMENTS 
This study was funded by Jeil Pharmaceutical Co., Ltd., Korea. 
REFERENCES
1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Con-
sensus Group. The Montreal definition and classification of gas-
troesophageal reflux disease: a global evidence-based consensus. 
Am J Gastroenterol 2006;101:1900-1920.
2. Richter JE. The many manifestations of gastroesophageal reflux 
disease: presentation, evaluation, and treatment. Gastroenterol 
Clin North Am 2007;36:577-599, viii-ix. 
3.  Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as 
a diagnostic tool in gastroesophageal reflux disease. Am J Gastro-
enterol 1997;92:1997-2000.
4. Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic as-
sessment of the omeprazole test in patients with symptoms 
suggestive of gastroesophageal reflux disease. Arch Intern Med 
1999;159:2161-2168. 
5.  Schindlbeck NE, Klauser AG, Voderholzer WA, Müller-Lissner SA. 
Empiric therapy for gastroesophageal reflux disease. Arch Intern 
Med 1995;155:1808-1812. 
6. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson 
L. One-week omeprazole treatment in the diagnosis of gastro-
oesophageal reflux disease. Scand J Gastroenterol 1998;33:15-20. 
7. Johnsson F, Hatlebakk JG, Klintenberg AC, et al. One-week 
esomeprazole treatment: an effective confirmatory test in patients 
with suspected gastroesophageal reflux disease. Scand J Gastroen-
terol 2003;38:354-359. 
countries, about 10-20%.
2,10 In Asia, the prevalence has been 
variably reported but is generally lower, 2.3-6.2%.
11 The preva-
lence of erosive esophagitis and non-erosive esophagitis in 
Korean has been reported to be 8% and 4%, respectively.
12 The 
difference of prevalence between Western and Asian countries 
may be due to genetic and/or environmental factors.
13 But, the 
prevalence of GERD may also change according to the methods 
used for the diagnosis of GERD, because there are several crite-
ria/method for the diagnosis of GERD. 
The PPI test has been used as an effective method for diag-
nosing GERD.
3,4 However, the dosage, duration, and optimal 
cut-off values are poorly defined. Several studies have used 
high dose of PPI for the inhibition of strong acid-secretion.
4,5,8 
Schindlbeck et al.
5 reported that the sensitivity of PPI testing 
using 40 mg and 80 mg omeprazole was 27% and 83.3%, re-
spectively. The definition of a positive PPI test in this study was 
a 75% reduction of symptoms. They concluded that GERD could 
be ruled out if symptoms do not improve with high dose of PPI 
testing. But, Fass et al.
4 had demonstrated that the sensitivity of 
omeprazole (60 mg daily, 40 mg AM+20 mg PM) test was about 
80%. Thus, no definite consensus about ideal dose for PPI test 
has been reached.
The results of this study showed no difference between the 
standard dose (30 mg) and high dose (60 mg) of lansoprazole 
to relieve the symptoms associated with GERD. The racial dif-
ference may contribute to this phenomenon. Thus, we proposed 
that the dose of PPI should be modulated by the population 
treated, especially with regard to race. 
The optimal duration of the PPI test is defined poorly. In most 
studies, the duration of PPI test is 7-14 days.
3-6,8,14 This duration 
was supported by a previous pharmacological study.
15 Previous 
study reported that in cases with atypical symptoms, 7 days of 
PPI test might be too short. Thus, 14 days in this study might be 
sufficient for duration of PPI test, because patients in this study 
had typical symptoms of GERD. 
The optimal cut-off value is also important to determine the 
accuracy of PPI test. In a previous study, the cut-off value was 
a 50-75% improvement in symptoms.
8,14 In this study, a positive 
PPI test was defined as a 50% improvement in the symptoms 
during 2 weeks. In addition, relief of symptoms according to 
the presence of erosive esophagitis was evaluated. A positive 
PPI test was observed 93.2% of patients in the ERD group and 
87.2% of patients in the NERD group. The duration to signifi-
cant symptom resolution was 6 days in the ERD group and 11 
days in the NERD group. In addition, a positive PPI test was 
observed 91.7% of those taking 15 mg, 89.4% of those taking 
30 mg and 87.2% of those taking 60 mg of lansoprazole. The 
duration to significant symptom resolution was 8 days in 15 
mg, 30 mg group, and 11 days in 60 mg of lansoprozole. This 
study showed that there was no difference in the rate of symp-
tom resolution between ERD and NERD group. Also, the dosage 
of lansoprazole did not influence the rate of symptom relief in Lee SH, et al: Appropriate Dose of Diagnostic Proton Pump Inhibitor Test  307
8. Juul-Hansen P, Rydning A, Jacobsen CD, Hansen T. High-dose 
proton-pump inhibitors as a diagnostic test of gastro-oesophageal 
reflux disease in endoscopic-negative patients. Scand J Gastroen-
terol 2001;36:806-810.
9. DeVault KR, Castell DO; American College of Gastroenterology. 
Updated guidelines for the diagnosis and treatment of gastro-
esophageal reflux disease. Am J Gastroenterol 2005;100:190-200. 
10. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology 
of gastro-oesophageal reflux disease: a systematic review. Gut 
2005;54:710-717. 
11. Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum 
and health care utilization of gastro-oesophageal reflux disease in 
a Chinese population: a population-based study. Aliment Pharma-
col Ther 2003;18:595-604. 
12. Kim N, Lee SW, Cho SI, et al. The prevalence of and risk factors 
for erosive oesophagitis and non-erosive reflux disease: a nation-
wide multicentre prospective study in Korea. Aliment Pharmacol 
Ther 2008;27:173-185. 
13. Cho YS, Choi MG, Jeong JJ, et al. Prevalence and clinical spec-
trum of gastroesophageal reflux: a population-based study in 
Asan-si, Korea. Am J Gastroenterol 2005;100:747-753. 
14. Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty 
MB. The omeprazole test is as sensitive as 24-h oesophageal pH 
monitoring in diagnosing gastro-oesophageal reflux disease in 
symptomatic patients with erosive oesophagitis. Aliment Pharma-
col Ther 2000;14:389-396. 
15.  Bruley des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, 
Galmiche JP. Comparison of lansoprazole with omeprazole on 24-
hour intragastric pH, acid secretion and serum gastrin in healthy 
volunteers. Aliment Pharmacol Ther 1994;8:309-314. 
16. des Varannes SB, Sacher-Huvelin S, Vavasseur F, et al. Rabepra-
zole test for the diagnosis of gastro-oesophageal reflux disease: 
results of a study in a primary care setting. World J Gastroenterol 
2006;12:2569-2573. 